Furthermore, the percentage of patients who used metformin and GLP-1 analogues, drugs that act not only on glycaemic control but also on cardiovascular risks due to their anti-inflammatory action, was higher in diabetic patients without lower limb ulcers than in either patients with DFS or healthy controls. The gene discussed is GLP1R; the disease is ulcer of lower limb.